title: What changes in inflammatory bowel disease management can be implemented today?
abstract: Innovative ideas are required to improve the management of inflammatory bowel disease and to share best practice that can be implemented into clinical practice today. The use of biomarkers such as calprotectin to monitor disease progression and treatment response could help to improve management of inflammatory bowel disease, but several strategies need to be implemented to make this a reality in clinical practice. The use of calprotectin as a biomarker and the manipulation of the thiopurine pathway to extend the use of current therapies are examples of how basic research can translate into patient benefit. Translational research into the use of microbiota and predictive factors for response and toxicity to drugs, may provide future clinical applications. Global improvement in care in inflammatory bowel disease could also be advanced by improving service provision. For example, the establishment of 'Centres of Excellence', a global interactive inflammatory disease map, and the alignment of processes and standards of care within treatment centres may help to achieve better outcomes for patients with inflammatory bowel disease. Realization of this goal, as well as a better understanding of the aetiology of the disease, may be furthered by collaborative efforts between organizations involved in inflammatory bowel disease as well as wider collaboration across countries and globally.
authors.affiliation: Department of Gastroenterology, Centre Hospitalier Universitaire de Liège, Liège, Belgium. edouard.louis@ulg.ac.be
authors.forename: Edouard
authors.initials: E
authors.lastname: Louis
authors.forename: Daniel C
authors.initials: DC
authors.lastname: Baumgart
authors.forename: Subrata
authors.initials: S
authors.lastname: Ghosh
authors.forename: Fernando
authors.initials: F
authors.lastname: Gomollón
authors.forename: Stephen
authors.initials: S
authors.lastname: Hanauer
authors.forename: Ailsa
authors.initials: A
authors.lastname: Hart
authors.forename: Peter
authors.initials: P
authors.lastname: Irving
mesh_terms: D015415:Biomarkers / Q000378:metabolism; D018450:Disease Progression; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000378:metabolism / Q000628:therapy*; D033183:Interdisciplinary Communication; D039841:Leukocyte L1 Antigen Complex / Q000378:metabolism; D008991:Monitoring, Physiologic; D011787:Quality of Health Care; D012074:Remission Induction; D057170:Translational Research, Biomedical; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D039841:Leukocyte L1 Antigen Complex